Paclitaxel Protein-Bound Particles

for injectable suspension (Albumin-Bound)

A solvent-free, albumin-
bound formulation

Actor portrayal

Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) is Paclitaxel bound to human-derived albumin

  • Formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers
  • A microtubule inhibitor
  • A solvent-free formulation

Premedication for hypersensitivity is generally not required

  • Premedication may be needed in patients who had prior hypersensitivity reactions to Paclitaxel Protein-Bound Particles

Paclitaxel Protein-Bound Particles can be infused over 30-40 minutes.

Paclitaxel Protein-Bound Particles Injectable Suspension is indicated for the treatment of

Metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

Product Specific Billing Code - J9259
Injection, paclitaxel protein-bound particles, 1 mg



Download the Billing and Coding Guide >